Lung cancer as a global health challenge: Multidimensional biomarker research and therapeutic advances - PubMed
4 hours ago
- #biomarkers
- #AI in oncology
- #lung cancer
- Lung cancer is the leading cause of global cancer-related mortality, categorized into small-cell and non-small-cell subtypes.
- Non-small-cell lung cancer (NSCLC) is further subcategorized into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each with distinct molecular alterations.
- Traditional serum biomarkers face limitations like poor specificity due to inflammatory confounders and difficulty in tracking therapeutic resistance dynamically.
- Emerging biomarkers reflect metabolic reprogramming, epigenetic dysregulation, stemness signatures, and immune microenvironment interactions.
- Liquid biopsies, integrating ctDNA, exosomal RNAs, and urinary DNA with multi-analyte panels and advanced imaging, enhance early detection and therapy monitoring.
- Challenges in clinical adoption include incomplete validation, technical standardization, intratumoral heterogeneity, and inter-ethnic variability.
- AI-enhanced multi-omics combined with biomarker-guided therapeutics could transform lung cancer into a manageable chronic disease.
- Prioritizing clinically validated AI-integrated platforms is crucial for achieving precision oncology.